Plasmatic ADAMTS-13 metalloprotease and von Willebrand factor in children with cyanotic congenital heart disease
暂无分享,去创建一个
[1] A. Kaider,et al. Loss of high-molecular-weight von Willebrand factor multimers mainly affects platelet aggregation in patients with aortic stenosis , 2009, Thrombosis and Haemostasis.
[2] J. Deckers,et al. Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. , 2009, Atherosclerosis.
[3] Ji-Eun Kim,et al. Correlation between plasma activity of ADAMTS-13 and coagulopathy, and prognosis in disseminated intravascular coagulation. , 2009, Thrombosis research.
[4] Z. Prohászka,et al. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia , 2009, Thrombosis and Haemostasis.
[5] M. Bauer,et al. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure , 2009, Thrombosis and Haemostasis.
[6] X. Zheng,et al. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells , 2008, Journal of thrombosis and haemostasis : JTH.
[7] J. Sadler. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. , 2008, Blood.
[8] M. Woodward,et al. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack , 2008, Journal of thrombosis and haemostasis : JTH.
[9] B. Lämmle,et al. ADAMTS‐13, von Willebrand factor and related parameters in severe sepsis and septic shock , 2007, Journal of thrombosis and haemostasis : JTH.
[10] G. Lippi,et al. Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications , 2007, Thrombosis journal.
[11] P. Mannucci,et al. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis , 2007, British journal of haematology.
[12] M. Omata,et al. Hepatic stellate cell damage may lead to decreased plasma ADAMTS13 activity in rats , 2007, FEBS letters.
[13] A. Nierich,et al. Relatively increased von Willebrand factor activity after off-pump coronary artery bypass graft surgery , 2006, Thrombosis and Haemostasis.
[14] H. Tsai. ADAMTS13 and microvascular thrombosis , 2006, Expert review of cardiovascular therapy.
[15] J. Child,et al. Pathogenesis of thrombocytopenia in cyanotic congenital heart disease. , 2006, The American journal of cardiology.
[16] J. Moake,et al. Human endothelial cells synthesize and release ADAMTS‐13 , 2006, Journal of thrombosis and haemostasis : JTH.
[17] Toshio Mori,et al. Localization of ADAMTS13 to the stellate cells of human liver. , 2005, Blood.
[18] Sanjeev Gupta,et al. ADAMTS13 is expressed in hepatic stellate cells , 2005, Laboratory Investigation.
[19] P. Mannucci,et al. Opposite changes of ADAMTS‐13 and von Willebrand factor after cardiac surgery , 2005, Journal of thrombosis and haemostasis : JTH.
[20] D. Lane,et al. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. , 2005, Blood.
[21] A. Lopes,et al. A mathematical framework for group analysis of von Willebrand factor multimeric composition following luminography. , 2002, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[22] G. White,et al. Clinical Use of a Rapid Collagen Binding Assay for von Willebrand Factor Cleaving Protease in Patients with Thrombotic Thrombocytopenic Purpura , 2002, Thrombosis and Haemostasis.
[23] H. Tsai. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura , 2002, Journal of Molecular Medicine.
[24] P. Mannucci,et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. , 2001, Blood.
[25] A. Sala,et al. Proteolysis of von Willebrand Factor and Shear Stress–Induced Platelet Aggregation in Patients With Aortic Valve Stenosis , 2000, Circulation.
[26] D. Devine,et al. Hemostatic Parameters and Platelet Activation Marker Expression in Cyanotic and Acyanotic Pediatric Patients Undergoing Cardiac Surgery in the Presence of Tranexamic Acid , 2000, Thrombosis and Haemostasis.
[27] P. Wang,et al. Organ dysfunction following hemorrhage and sepsis: mechanisms and therapeutic approaches (Review). , 1999, International journal of molecular medicine.
[28] H. Schwarz,et al. The determination of von Willebrand factor activity by collagen binding assay , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.
[29] W. Williams,et al. Effect of heparin loading during congenital heart operation on thrombin generation and blood loss. , 1997, The Annals of thoracic surgery.
[30] M. Seear,et al. The effect of preoperative tranexamic acid on blood loss after cardiac operations in children. , 1996, The Journal of thoracic and cardiovascular surgery.
[31] T. Mayadas,et al. Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation. , 1996, The Journal of clinical investigation.
[32] C. Wollheim,et al. Reactive oxygen intermediates induce regulated secretion of von Willebrand factor from cultured human vascular endothelial cells. , 1995, Blood.
[33] D. Crossman,et al. Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cells. , 1990, Blood.
[34] J. Pober,et al. IL-1 and related cytokines enhance thrombin-stimulated PGI2 production in cultured endothelial cells without affecting thrombin-stimulated von Willebrand factor secretion or platelet-activating factor biosynthesis. , 1989, Journal of immunology.
[35] A. Schorer,et al. Interleukin 1 or endotoxin increases the release of von Willebrand factor from human endothelial cells , 1987, British journal of haematology.
[36] C. Francis,et al. Fibrin induces release of von Willebrand factor from endothelial cells. , 1987, The Journal of clinical investigation.